pioglitazone + candesartan

Pioglitazone + candesartan is a combination therapy used primarily for patients with hypertension and type 2 diabetes mellitus. Pioglitazone is a thiazolidinedione class anti-diabetic agent that improves insulin resistance, while candesartan is an angiotensin receptor blocker (ARB) that controls blood pressure. This combination has demonstrated efficacy in simultaneously improving both blood pressure and glycemic control. Clinical studies have shown that the combination therapy provides anti-inflammatory effects and organ-protective benefits beyond what either medication achieves alone. The combination has been shown to reduce urinary albumin excretion, suggesting potential renoprotective effects. Additionally, it has been found to improve markers of inflammation such as high-molecular-weight adiponectin (HMW-ADN) and plasminogen activator inhibitor-1 (PAI-1).

Other names

candesartan cilexetil + pioglitazone hydrochlorideCC/PIO